Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast for Cognitive Impairment in Schizophrenia
NCT02079844Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of roflumilast in schizophrenia (3 arms), sponsored by Takeda. Primary endpoints: Change From Baseline in Spatial Span Test Score at Day 8, Change From Baseline in Hopkins Verbal Learning Test Score at Day 8 and 1 more. Started Mar 2014; status: completed.
02
Drugs
roflumilast
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02079844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079844.